Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: JamesK who wrote (51907)	1/19/2022 12:32:24 PM
From: Art Bechhoefer	1 Recommendation Recommended By Lance Bredvold Read Replies (1) \| Respond to of 52153

There has been a gradual decline in prices of numerous small and medium size biotech firms over the last several weeks on the premise that higher interest rates and inflation make these development stage firms, most of which pay no dividends and operate at a loss, less attractive. Larger firms, like AstraZeneca, which pay dividends, no matter whether they have large debts, have retained their share price, even if it is not going up much, if at all. The main issues, as I see it, are (1) a very short term outlook on the part of large scale investors and traders, and (2) fear that proposed government regulations on pricing of certain high priced prescription drugs will reduce drug profits substantially. There's no possibility of changing the minds of investors geared to short term profits, but the very existence of large numbers of investors with similar mindset has led to many smaller, development stage biotechs performing poorly. As for proposed government regulations (part of the Build Back better legislation going nowhere fast in Congress), every instance for more than 60 years, when drugs were made more available to the general public, drug company profits have gone up considerably. To lobby against government on the notion that its regulations will interfere with higher profits is nonsense. Art